Dr. James Clinton is an expert at developing advanced cell biology models for the scientific community. Watch his presentation to gain an overview of the Human Cancer Models Initiative (HCMI), and of the technologies driving the development of these “next-generation” models that hold promise to transform in vitro cancer research.
- There is an unmet need for novel preclinical cancer models that better reflect the genotype and phenotype across the spectrum of cancer found in the patient population.
- The HCMI is funded by the National Cancer Institute, Cancer Research UK, Wellcome Sanger Institute, and the foundation Hubrecht Organoid Technology, and seeks to generate 1000 novel cancer models that will be manufactured and distributed by ATCC.
- A wide variety of patient-derived in vitro cancer models are offered, including 3D organoids and neurospheres, as well as conditionally reprogrammed cells and other 2D models.